CliffBio
small molecule

FETZIMA

LEVOMILNACIPRAN HYDROCHLORIDE

Loss of exclusivityMay 2032latest FDA-listed patent expiry
CompanyAbbVie Inc. →View the full company profile on CliffBio

Drug detail

Brand nameFETZIMA
Active ingredientLEVOMILNACIPRAN HYDROCHLORIDE
StrengthEQ 20MG BASE
Dosage formCAPSULE, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalJuly 2013
Marketing statusRX

Listed patents

PatentExpiresType
8865937May 2032substance, product
8481598March 2031use U-839
RE43879January 2026use U-839

Regulatory exclusivity

CodeExpires
M-304March 2026

More from AbbVie Inc.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

FETZIMA patent cliff — loss of exclusivity May 2032 | CliffBio